A phase II study of imatinib in patients with advanced anaplastic thyroid cancer.


BACKGROUND Currently, there is no standard treatment for metastatic anaplastic thyroid cancer (ATC). DNA microarray analysis has shown platelet-dervived growth factor receptor (PDGFR) overexpression in ATC relative to well-differentiated thyroid cancer. In p53-mutated/deficient ATC cell lines, cABL is overexpressed, and selective inhibition of cABL results… (More)
DOI: 10.1089/thy.2010.0057

4 Figures and Tables


  • Presentations referencing similar topics